Стронций-89-хлорид в комплексном лечении гормонорезистентного рака предстательной железы

1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2001 г. – М., 2003. – С. 7–10; 100–102.

2. Partin A.W., Yoo J., Carter H.B. et al. The use of prostate specific antigen clinical stage Gleason and reason score to predict pathological stage in men with localized prostate cancer // J. Urol. – 1993; 150:110.

3. Scher H., Steinneck G., Kelly W.K. Hormone-refractory (D3) prostate cancer: refining the concept // Urology. – 1995; 46:142–148.

4. Vogelzang N.J., Crawford E.D., Zietman A. Current clinical trial design issues in hormone-refractory prostate cancer // Cancer. – 1998; 82:2093–2101.

5. Babley G.J., Carducci M., Dahur W. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group // J. Clin. Oncol. – 1999; 17:3461–3467.

6. Goodin S., Rao K.V., DiPaola R.S. State-of-the-art treatment of metastatic hormone-refractory prostate cancer // Oncologist. – 2002; 7(4):360–370.

7. Rosental M.A. Advanced in the management of prostate cancer // Austral. N. Z. J. Med. – 2000; 30(5):593–599.

8. Isaacs J.T. The biology of hormone-factory prostate cancer. Why does it develop? // Urol. Clin. North. Am. – 1999; 26:263–273.

9. Oh W.K., Kanthoff P.W. Management of hormone refractory prostate cancer: current standarts and future prostests // J. Urol. – 1998; 160:1220–1229.

10. Kirby R.S., Christmas T.J., Brawer M.K. et al. Prostate cancer // Second. edition. – 2001; 187–198.